Open Access

Making sense of antisense

  • Jonathan B Weitzman
Genome Biology20012:spotlight-20010820-01

https://doi.org/10.1186/gb-spotlight-20010820-01

Published: 20 August 2001

The specificity of antisense approaches is much debated and has hampered their development for clinical therapeutics. In the August 14 Proceedings of the National Academy of Sciences, Yee Cho and colleagues at the National Institutes of Health, Bethesda, MD, report the use of DNA microarrays to resolve aspects of the mechanism of antisense action (Proc Natl Acad Sci USA 2001, 98:9819-9823). They investigated the effects of antisense oligonucleotides targeting the regulatory RIα subunit of cAMP-dependent protein kinase (PKA). They treated human PC3 prostate cancer cells with antisense phosphorothioate oligonucleotides (PS-ODNs) or with 2'-O-methyl RNA/DNA hybridODNs and examined changes in the expression profiles of over 2,300 genes. Expression of about 10% of the genes was altered by antisense treatment. The results were very similar whether exogenous ODNs or endogenous antisense gene overexpression were used. RIα antisense treatment affected a specific subset of genes, causing decreased expression of proliferation-related gene clusters, and boosted the expression of differentiation-related genes. Defining gene expression profiles upon antisense treatment may help to answer some of the concerns about ODN-directed antisense strategies in the clinic.

References

  1. Potential roles of antisense technology in cancer chemotherapy.Google Scholar
  2. Proceedings of the National Academy of Sciences, [http://www.pnas.org]
  3. National Institutes of Health, [http://www.nih.gov]
  4. The cAMP-dependent protein kinases and cAMP signal transduction.Google Scholar
  5. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.Google Scholar

Copyright

© BioMed Central Ltd 2001

Advertisement